Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2647 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-04-03 (investing.com)
RBC Capital cuts Biogen stock price target to $221 By
On Thursday, RBC Capital Markets adjusted its financial outlook on Biogen shares, reducing the price target to $221 from $225 while maintaining an Outperform rating. According to InvestingPro data, the stock is currently trading near its 52-week low of $128.51, with analyst targets ranging from $135 to $342, suggesting significant potential upside. The company maintains a healthy financial profile with an InvestingPro Financial Health score of "GOOD." Brian Abrahams of RBC Capital Markets shared insights on Biogen's quarterly performance, noting an expectation for revenues to align closely with consensus estimates at $2.25 billion versus the $2.24 billion forecast. This comes as the company's trailing twelve-month revenue stands at $9.68 billion, with a robust gross profit margin of 76%.
Read more
2025-03-31 (nasdaq.com)
Validea Detailed Fundamental Analysis - BIIB |
Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital
Read more
2025-03-08 (morningstar.se)
5 shares with the largest reductions of estimated fair value after the Q4 result
Stmicroelectronics and Biogen are among the shares that have the largest reductions.
Read more
2025-03-07 (nasdaq.com)
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints |
BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.
Read more
2025-03-07 (wsj.com)
Biogen Stock Falls After Company Gives Weaker-Than-Expected Financial Outlook
Biogen Stock Falls After Company Gives Weaker-Than-Expected Financial Outlook ... Biogen shares fell, after the biotechnology company forecast lower-than-expected...
Read more
2025-03-04 (investors.com)
Biogen Takes A Beating After Earnings Report. Here's Why.
Biogen (BIIB) stock took a hit Wednesday after the biotech company issued light guidance for 2025 despite beating most fourth-quarter expectations.
Read more
2025-02-13 (asianetnews.com)
Biogen Stock Slides To Fresh 12-Year Lows As Profit Outlook Misses, But Retail Snaps Up The Dip-
The company's breakthrough Alzheimer's drug, Leqembi, generated $87 million in Q4 sales, well ahead of the $67 million analysts expected.
Read more
2025-02-12 (alphastreet.com)
Key metrics from Biogen's (BIIB) Q4 2024 earnings results |
Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter 2024 earnings results today. Total revenue increased 3% year-over-year to $2.5 billion. Net income attributable to Biogen Inc. was $266.8 million, or $1.83 per share, compared to $249.7 million, or $1.71 per share, last year. Adjusted EPS grew 17% YoY to $3.44. For full-year 2025, […]
Read more
2025-02-12 (tradingview.com)
BIOGEN INC. SEC 10-K Report — News
Biogen Inc., a leading biopharmaceutical company specializing in neurological and rare disease treatments, has released its 2024 Form 10-K report. The report provides a comprehensive overview of the company's financial performance, business operations, strategic initiatives, and the challenges it f…
Read more